Tetanus toxoid, diphtheria toxoid, and Bordetella pertussis antigen (DTaP/Tdap)

Tetanus toxoid, diphtheria toxoid, and Bordetella pertussis antigens represent a composite set of immunogenic targets used in combination vaccines (DTaP and Tdap) to provide protection against three distinct bacterial diseases (CDC, 2023). The tetanus and diphtheria components are toxoids—chemically inactivated exotoxins that retain the ability to elicit neutralizing antibodies without causing systemic toxicity (DrugBank, 2024). The pertussis component typically consists of acellular antigens, including pertussis toxoid, filamentous hemagglutinin, and pertactin, which are essential for bacterial adhesion and pathogenesis (StatPearls, 2023). These antigens function by inducing a robust humoral immune response, characterized by the production of IgG antibodies that neutralize toxins and facilitate bacterial clearance (PubMed, 2022). Clinically, these targets are critical for preventing the neuromuscular blockade caused by tetanus toxin, the respiratory and systemic complications of diphtheria toxin, and the severe paroxysmal coughing associated with pertussis infection (WHO, 2023). The efficacy of these antigens is monitored through serological titers, and they remain a cornerstone of global pediatric and adult immunization programs.

Other names

DTaP antigensTdap antigensDTP antigensTetanus-Diphtheria-Pertussis combinationDiphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed

Active immunization through the induction of neutralizing antibodies against bacterial toxins and surface proteins.